CytomX Therapeutics, Inc. (NASDAQ:CTMX) Under Analyst Spotlight

Henrietta Brewer
October 7, 2017

Nomura upped their price target on CytomX Therapeutics to $44.00 and gave the company a "buy" rating in a research report on Wednesday. Over the last ninety days, insiders have sold 100,306 shares of company stock worth $1,924,746. After $-0.69 actual earnings per share reported by CytomX Therapeutics Inc for the previous quarter, Wall Street now forecasts -85.51 % EPS growth. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2017/10/06/cytomx-therapeutics-inc-ctmx-receives-outperform-rating-from-cowen-and-company.html.

In the last earnings report the EPS was $-1.70 and is estimated to be $-1.47 for the current year with 36,867,000 shares now outstanding. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million.

On the biobucks side, CytomX can look forward to $455 million for the EGFR program, and while Amgen will lead global sales activities, CytomX can opt into a profit share in the US and receive tiered, double-digit royalties on net product sales outside of the U.S.


Top Pick for Thursday: CytomX Therapeutics, Inc. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & global copyright & trademark legislation. BidaskClub raised CytomX Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 8th.

03/27/2017 - H.C. Wainwright began new coverage on CytomX Therapeutics, Inc. giving the company a "buy" rating. Oppenheimer maintained CytomX Therapeutics Inc (NASDAQ:CTMX) on Wednesday, June 28 with "Hold" rating. Below is a list of CytomX Therapeutics Inc (NASDAQ:CTMX) latest ratings and price target changes. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company has a consensus rating of "Hold" and an average price target of $32.67.

The Earnings to Price yield of CytomX Therapeutics, Inc. The company's market cap is $814.76 million. The 50 day moving average was up $4.91 and the 200 day average went up by +40.78%. CytomX Therapeutics has a 1-year low of $9.85 and a 1-year high of $24.67.


These funds have shifted positions in (CTMX). That suggests something of the likelihood of a short squeeze in shares of CTMX. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company's stock worth $343,000 after purchasing an additional 292 shares during the last quarter. The shares were purchased at an average price of $18.57.

As of quarter end Vident Investment Advisory, LLC had bought 7,468 shares growing its stake by 9.8%. Also, insider Sean A. Mccarthy sold 4,781 shares of the business's stock in a transaction dated Wednesday, August 9th. Legal & General Group Plc now owns 6,448 shares of the biotechnology company's stock worth $101,000 after acquiring an additional 1,434 shares during the period. If, for instance, a stock's volumes suddenly increase by a significant amount, it's usually a sign that the level of conviction behind the trade is high. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Following the completion of the sale, the chief financial officer now directly owns 19,626 shares in the company, valued at approximately $294,390. The shares were sold at an average price of $24.13, for a total value of $461,365.60. Dev. disclosed the sale of 48,368 shares of CTMX stock. As per Tuesday, January 3, the company rating was downgraded by Oppenheimer.

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, probody drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.


Probody T-cell engaging bispecifics are antibody constructs created to direct cytotoxic T-cells in tumour microenvironments, with preclinical studies showing that these types of drug can induce tumour regressions and increase the therapeutic window for this high-potential cancer target.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER